| Symbol | XNCR |
|---|---|
| Name | XENCOR INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 465 N. HALSTEAD ST., PASADENA, CA 91107 |
| Telephone | 626-305-5900 |
| Fax | — |
| — | |
| Website | https://www.xencor.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001326732 |
| Description | Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates. Additional info from NASDAQ: |
2026-07-31 11:47
New Form SCHEDULE 13G - Xencor Inc <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001489 <b>Size:</b> 7 KB
Read more
2026-07-29 20:05
(99% Neutral) XENCOR INC (XNCR) Provides Update on million for two equal payments
Read more
2026-07-29 20:01
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
Read more
2026-07-17 13:11
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Read more
2026-06-22 20:01
Director Feigal Ellen 🔴 sold 6.8K shares of Xencor Inc (XNCR) at $13.06 Transaction Date: Jun 18, 2026 | Filing ID: 000002
Read more
2026-06-18 13:38
📋 Feigal Ellen (Director) plans to sell 7K shares of Xencor Inc (at $13.06 each, total $89K) Filed: Jun 18, 2026 | ID: 004758
Read more
2026-06-17 20:02
Director GORMAN KEVIN CHARLES 🔴 sold 7.5K shares of Xencor Inc (XNCR) at $12.31 Transaction Date: Jun 15, 2026 | Filing ID: 000014
Read more
2026-06-17 20:01
Director GUSTAFSON KURT A 🔴 sold 5.5K shares of Xencor Inc (XNCR) at $12.31 Transaction Date: Jun 15, 2026 | Filing ID: 000004
Read more
2026-06-17 20:01
Director RANIERI RICHARD J 🔴 sold 5.5K shares of Xencor Inc (XNCR) at $12.31 Transaction Date: Jun 15, 2026 | Filing ID: 000002
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07713485 | Study of XmAb412 in Healthy Participants | Phase1 | Not Applicable - Healthy Adult Participants | Recruiting | 2026-07-13 | 2028-03-01 | ClinicalTrials.gov |
| NCT07593092 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid… | Phase1 | Ovarian Cancer | Recruiting | 2026-06-30 | 2028-12-01 | ClinicalTrials.gov |
| NCT07284797 | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Parti… | Phase1 | Healthy | Recruiting | 2026-02-24 | 2028-10-01 | ClinicalTrials.gov |
| NCT07230353 | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants Wi… | Phase1 | Rheumatoid Arthritis | Recruiting | 2025-10-21 | 2028-06-01 | ClinicalTrials.gov |
| NCT06619990 | Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colit… | Phase1 | Ulcerative Colitis (UC) | Recruiting | 2024-10-10 | 2029-01-01 | ClinicalTrials.gov |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Phase1 | Ovarian Cancer | Recruiting | 2024-04-04 | 2028-12-01 | ClinicalTrials.gov |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-l… | Phase1 | Nonsquamous Non-small Cell Lung Cancer | Terminated | 2023-12-27 | 2025-12-29 | ClinicalTrials.gov |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patient… | Phase1 | Castration-Sensitive Prostate Carcinoma | Terminated | 2023-08-03 | 2025-06-12 | ClinicalTrials.gov |
| NCT05996445 | A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Adva… | Phase1 | Solid Tumors | Terminated | 2023-07-28 | 2024-05-21 | ClinicalTrials.gov |
| NCT05900648 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Ca… | Phase2 | Colorectal Cancer | Withdrawn | 2023-05-17 | 2024-02-09 | ClinicalTrials.gov |
| NCT05879185 | A Study of XmAb23104 in People With Sarcoma | Phase2 | Sarcoma | Terminated | 2023-04-06 | 2024-07-19 | ClinicalTrials.gov |
| NCT05695898 | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior… | Phase1 | Metastatic Melanoma | Terminated | 2023-02-28 | 2024-04-29 | ClinicalTrials.gov |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 … | Phase1 | Head and Neck Squamous Cell Carcinoma | Completed | 2022-12-14 | 2025-05-20 | ClinicalTrials.gov |
| NCT06005792 | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopi… | Phase1 | Psoriasis | Terminated | 2022-10-10 | 2024-11-22 | ClinicalTrials.gov |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic … | Phase2 | Ovarian Cancer | Active_Not_Recruiting | 2022-07-21 | 2025-12-30 | ClinicalTrials.gov |
| NCT05433142 | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Phase1 | Clear Cell Renal Cell Carcinoma | Recruiting | 2022-06-13 | 2028-12-01 | ClinicalTrials.gov |
| NCT05328102 | Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus … | Phase2 | Diffuse Large-cell B-cell Lymphoma | Terminated | 2022-04-15 | 2023-02-21 | ClinicalTrials.gov |
| NCT05297903 | XmAb20717 in Advanced Biliary Tract Cancers | Phase2 | Biliary Tract Cancer | Active_Not_Recruiting | 2022-04-11 | 2026-12-02 | ClinicalTrials.gov |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Th… | Phase2 | Metastatic Castration-Resistant Prostate Cancer | Completed | 2021-10-22 | 2025-06-10 | ClinicalTrials.gov |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcin… | Phase1 | Merkel Cell Carcinoma | Terminated | 2021-05-10 | 2022-03-24 | ClinicalTrials.gov |
| NCT04857866 | Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in … | Phase1 | Safety in Healthy Volunteers | Completed | 2021-04-19 | 2022-11-10 | ClinicalTrials.gov |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects… | Phase1 | Melanoma | Completed | 2019-05-29 | 2023-02-16 | ClinicalTrials.gov |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | Phase1 | Melanoma (Excluding Uveal Melanoma) | Completed | 2019-05-01 | 2024-02-15 | ClinicalTrials.gov |
| NCT03445663 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma | Phase1 | Relapsed/ Refractory Multiple Myeloma | Terminated | 2018-07-31 | 2020-06-19 | ClinicalTrials.gov |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | Phase1 | Melanoma | Completed | 2018-07-10 | 2022-09-06 | ClinicalTrials.gov |
| NCT03411915 | A Study of XmAb®18087 in Subjects With NET and GIST | Phase1 | Neuroendocrine Tumor | Completed | 2018-01-22 | 2021-10-26 | ClinicalTrials.gov |
| NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients… | Phase1 | B-cell Non-Hodgkins Lymphoma | Completed | 2016-10-01 | 2024-04-01 | ClinicalTrials.gov |
| NCT02881853 | Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7… | Phase1 | Healthy Volunteers | Completed | 2016-08-17 | 2017-02-24 | ClinicalTrials.gov |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD… | Phase1 | Acute Myelogenous Leukemia | Completed | 2016-08-01 | 2021-09-01 | ClinicalTrials.gov |
| NCT02867098 | XmAb5871 Bioavailability Study | Phase1 | Healthy Volunteers | Completed | 2016-07-01 | 2016-10-21 | ClinicalTrials.gov |
| NCT02725476 | Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With … | Phase2 | IgG4-RD | Completed | 2016-03-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT02725515 | A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus | Phase2 | Systemic Lupus Erythematosus | Completed | 2016-02-16 | 2018-07-17 | ClinicalTrials.gov |
| NCT02148744 | Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subj… | Phase1 | Allergic Rhinitis | Completed | 2014-05-01 | 2015-09-21 | ClinicalTrials.gov |
| NCT01161511 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | Phase1 | Chronic Lymphocytic Leukemia | Completed | 2010-09-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00606645 | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Ly… | Phase1 | Hodgkin Lymphoma | Completed | 2007-12-01 | 2010-04-01 | ClinicalTrials.gov |
Total clinical trials: 35
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06276491 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT07593092 |
| Placebo | Other | Phase PHASE1 | Not Applicable - Healthy Adult Participants | RECRUITING | NCT07713485 |
| XmAb412 Monoclonal Bispecific Antibody | Other | Phase PHASE1 | Not Applicable - Healthy Adult Participants | RECRUITING | NCT07713485 |
| Plamotamab | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT07230353 |
| XmAb819 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05433142 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Not Applicable - Healthy Adult Participants | RECRUITING | NCT07713485 |
| XmAb412 Monoclonal Bispecific Antibody | Other | Phase PHASE1 | Not Applicable - Healthy Adult Participants | RECRUITING | NCT07713485 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06276491 |
| XmAb819 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05433142 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb808 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | NOT_YET_RECRUITING | NCT07593092 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| XmAb657 | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07284797 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + cabazitaxel or docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + docetaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab monotherapy | Drug | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + olaparib | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| vudalimab + carboplatin + cabazitaxel | Other | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| XmAb5574 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01161511 |
| Placebo | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT02148744 |
| XmAb7195 | Other | Phase PHASE1 | Allergic Rhinitis | COMPLETED | NCT02148744 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02881853 |
| XmAb7195 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02881853 |
| XmAb5871 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02867098 |
| XmAb5871 | Other | Phase PHASE2 | IgG4-RD | COMPLETED | NCT02725476 |
| Placebo to match XmAb5871 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02725515 |
| XmAb5871 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02725515 |
| XmAb14045 | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT02730312 |
| XmAb18087 | Other | Phase PHASE1 | Neuroendocrine Tumor | COMPLETED | NCT03411915 |
| XmAb20717 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03517488 |
| Placebo | Other | Phase PHASE1 | Safety in Healthy Volunteers | COMPLETED | NCT04857866 |
| XmAb27564 | Other | Phase PHASE1 | Safety in Healthy Volunteers | COMPLETED | NCT04857866 |
| AMG 424 | Other | Phase PHASE1 | Relapsed/ Refractory Multiple Myeloma | TERMINATED | NCT03445663 |
| Pembrolizumab (Keytruda®) | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03849469 |
| XmAb®22841 | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT03849469 |
| XmAb18087 ± Pembrolizumab | Other | Phase PHASE1 | Merkel Cell Carcinoma | TERMINATED | NCT04590781 |
| XmAb18087 | Other | Phase PHASE1 | Merkel Cell Carcinoma | TERMINATED | NCT04590781 |
| XmAb20717 | Other | Phase PHASE2 | Colorectal Cancer | WITHDRAWN | NCT05900648 |
| Regorafenib | Other | Phase PHASE2 | Colorectal Cancer | WITHDRAWN | NCT05900648 |
| Lenalidomide | Other | Phase PHASE2 | Diffuse Large-cell B-cell Lymphoma | TERMINATED | NCT05328102 |
| Tafasitamab | Other | Phase PHASE2 | Diffuse Large-cell B-cell Lymphoma | TERMINATED | NCT05328102 |
| Plamotamab | Other | Phase PHASE2 | Diffuse Large-cell B-cell Lymphoma | TERMINATED | NCT05328102 |
| Yervoy® (ipilimumab) | Other | Phase PHASE1 | Melanoma (Excluding Uveal Melanoma) | COMPLETED | NCT03752398 |
| XmAb®23104 | Other | Phase PHASE1 | Melanoma (Excluding Uveal Melanoma) | COMPLETED | NCT03752398 |
| Keytruda® (pembrolizumab) | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05996445 |
| XmAb662 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05996445 |
| XmAb13676 | Other | Phase PHASE1 | B-cell Non-Hodgkins Lymphoma | COMPLETED | NCT02924402 |
| vudalimab | Other | Phase PHASE2 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05032040 |
| XmAb23104 | Other | Phase PHASE1 | Metastatic Melanoma | TERMINATED | NCT05695898 |
| XmAb22841 | Other | Phase PHASE1 | Metastatic Melanoma | TERMINATED | NCT05695898 |
| Keytruda® (pembrolizumab) | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT05585034 |
| XmAb®808 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT05585034 |
| Vudalimab | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| PSMA PET Scan | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Magnetic Resonance Imaging | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| FDG-Positron Emission Tomography | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Enzalutamide | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Docetaxel | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Computed Tomography | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Bone Scan | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Biospecimen Collection | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Abiraterone | Other | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| XmAb20717 | Other | Phase PHASE2 | Biliary Tract Cancer | ACTIVE_NOT_RECRUITING | NCT05297903 |
| Placebo | Other | Phase PHASE1 | Psoriasis | TERMINATED | NCT06005792 |
| XmAb27564 | Other | Phase PHASE1 | Psoriasis | TERMINATED | NCT06005792 |
| XmAb13676 | Other | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT07284797 |
| XmAb819 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05433142 |
| Pembrolizumab + Carboplatin + Pemetrexed | Other | Phase PHASE1 | Nonsquamous Non-small Cell Lung Cancer | TERMINATED | NCT06173505 |
| Vudalimab + Carboplatin + Pemetrexed | Other | Phase PHASE1 | Nonsquamous Non-small Cell Lung Cancer | TERMINATED | NCT06173505 |
| XmAb541 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06276491 |
| Placebo | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb942 | Other | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb23104 | Other | Phase PHASE2 | Sarcoma | TERMINATED | NCT05879185 |
| Plamotamab | Other | Phase PHASE1 | Rheumatoid Arthritis | RECRUITING | NCT07230353 |
| XmAb942 | BIOLOGICAL | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb541 | BIOLOGICAL | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT06276491 |
| XmAb662 | BIOLOGICAL | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05996445 |
| Regorafenib | DRUG | Phase PHASE2 | Colorectal Cancer | WITHDRAWN | NCT05900648 |
| Vudalimab | DRUG | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| PSMA PET Scan | PROCEDURE | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Magnetic Resonance Imaging | PROCEDURE | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| FDG-Positron Emission Tomography | PROCEDURE | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Enzalutamide | DRUG | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Docetaxel | DRUG | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Computed Tomography | PROCEDURE | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Bone Scan | PROCEDURE | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Biospecimen Collection | PROCEDURE | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| Abiraterone | DRUG | Phase PHASE1 | Castration-Sensitive Prostate Carcinoma | TERMINATED | NCT05733351 |
| XmAb23104 | BIOLOGICAL | Phase PHASE2 | Sarcoma | TERMINATED | NCT05879185 |
| XmAb22841 | DRUG | Phase PHASE1 | Metastatic Melanoma | TERMINATED | NCT05695898 |
| Keytruda® (pembrolizumab) | BIOLOGICAL | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05996445 |
| XmAb®808 | BIOLOGICAL | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT05585034 |
| XmAb819 | BIOLOGICAL | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | RECRUITING | NCT05433142 |
| Lenalidomide | DRUG | Phase PHASE2 | Diffuse Large-cell B-cell Lymphoma | TERMINATED | NCT05328102 |
| Tafasitamab | BIOLOGICAL | Phase PHASE2 | Diffuse Large-cell B-cell Lymphoma | TERMINATED | NCT05328102 |
| Plamotamab | BIOLOGICAL | Phase PHASE2 | Diffuse Large-cell B-cell Lymphoma | TERMINATED | NCT05328102 |
| vudalimab | BIOLOGICAL | Phase PHASE2 | Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT05032040 |
| vudalimab monotherapy | BIOLOGICAL | Phase PHASE2 | Metastatic Castration-Resistant Prostate Cancer | COMPLETED | NCT05005728 |
| XmAb27564 | BIOLOGICAL | Phase PHASE1 | Psoriasis | TERMINATED | NCT06005792 |
| XmAb18087 ± Pembrolizumab | DRUG | Phase PHASE1 | Merkel Cell Carcinoma | TERMINATED | NCT04590781 |
| Pembrolizumab (Keytruda®) | BIOLOGICAL | Phase PHASE1 | Melanoma | COMPLETED | NCT03849469 |
| XmAb®22841 | BIOLOGICAL | Phase PHASE1 | Melanoma | COMPLETED | NCT03849469 |
| Yervoy® (ipilimumab) | BIOLOGICAL | Phase PHASE1 | Melanoma (Excluding Uveal Melanoma) | COMPLETED | NCT03752398 |
| XmAb®23104 | BIOLOGICAL | Phase PHASE1 | Melanoma (Excluding Uveal Melanoma) | COMPLETED | NCT03752398 |
| XmAb20717 | DRUG | Phase PHASE2 | Colorectal Cancer | WITHDRAWN | NCT05900648 |
| AMG 424 | DRUG | Phase PHASE1 | Relapsed/ Refractory Multiple Myeloma | TERMINATED | NCT03445663 |
| XmAb18087 | BIOLOGICAL | Phase PHASE1 | Merkel Cell Carcinoma | TERMINATED | NCT04590781 |
| XmAb13676 | BIOLOGICAL | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT07284797 |
| XmAb14045 | BIOLOGICAL | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT02730312 |
| Placebo to match XmAb5871 | BIOLOGICAL | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT02725515 |
| XmAb5871 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02867098 |
| Placebo | DRUG | Phase PHASE1 | Ulcerative Colitis (UC) | RECRUITING | NCT06619990 |
| XmAb7195 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02881853 |
| XmAb5574 | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | COMPLETED | NCT01161511 |
| XmAb2513 | BIOLOGICAL | Phase PHASE1 | Hodgkin Lymphoma | COMPLETED | NCT00606645 |
Total products: 260